Search
for
Sort by
Research 271–300 of 1000+
- Hair Loss in Lichen Planopilaris and Frontal Fibrosing Alopecia: Not Always Irreversible
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
- Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
- Janus Kinase Inhibitors against Other Biological Treatments in Alopecia Areata
- “Two-Cell Assemblage” Assay: A Simple in vitro Method for Screening Hair Growth-Promoting Compounds
- Immune therapies for alopecia areata: evidence and new perspectives
- Childhood Alopecia Areata: An Overview of Treatment and Recent Patents
- A review of Janus kinase inhibitor use in scarring alopecia
- A Potential Role for IL-4 and IL-13 in an Alopecia Areata–Like Phenotype: A Clinical Perspective
- [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
- Bletilla striata polysaccharide-based dissolving microneedle patch integrated with nanoparticles for promoting hair regrowth
- Drugs targeting epithelial–mesenchymal transition molecules for treatment of lichen planopilaris
- 691 Topical curcumin promotes induction of the murine hair cycle
- Alopecia areata: medical treatments
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Efficacy and safety of JAK inhibitors in treating lichen planopilaris or frontal fibrosing alopecia
- JAK inhibition decreases the autoimmune burden in Down syndrome
- A Bibliometric Analysis of Alopecia Areata Literature over the Past 50 Years.
- The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
- Janus kinase inhibitors for alopecia areata: A narrative review
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Topical SCD-153, a 4-methyl itaconate prodrug, for the treatment of alopecia areata
- Not just thinning: A case of alopecia universalis after mild COVID-19
- Alopecia areata – Aktuelles Verständnis und Management
- Two Birds that Exclude Each Other: The Renbök Phenomenon
- Biologics and Small Molecules for Inflammatory Nail Disorders: A Narrative Review
- Efficacy, safety, and Pharmacoeconomics of Three Common Strategies for Pediatric Alopecia Areata Patients: A Retrospective Cohort Study
- Alopecia areata: from pathophysiology to therapeutic innovation
- Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs